|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S1
|
$48,687
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S2
|
$85,299
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S3
|
$47,040
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
5U54CA163071-07
|
$1,619,382
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(2/2) TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership
|
1U54CA221704-01A1
|
$1,050,067
|
OGUNWOBI, OLORUNSEUN
|
HUNTER COLLEGE
|
|
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors
|
3R01CA227473-01S1
|
$293,469
|
HEROLD, KEVAN
|
YALE UNIVERSITY
|
|
(ACCSIS) Accelerating Colorectal Cancer Screening through Implementation Science in Appalachia
|
1UG3CA233282-01
|
$770,562
|
DIGNAN, MARK
|
UNIVERSITY OF KENTUCKY
|
|
(PQ #10) Gut-brain interactions underlying chemotherapy-induced behavioral comorbidities
|
5R01CA216290-02
|
$309,819
|
PYTER, LEAH
|
OHIO STATE UNIVERSITY
|
|
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
|
3R01CA206025-03S1
|
$52,355
|
GUISE, THERESA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
(PQ12) Peroxisome proliferator-activated receptor alpha agonists as potential treatment for chemotherapy-induced peripheral neuropathy
|
1R01CA219637-01A1
|
$281,441
|
DAMAJ, M IMAD
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
|
1R01CA231325-01
|
$572,540
|
CURIEL, TYLER
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
|
(PQ3) Immune epigenetic biomarkers of bladder cancer outcomes
|
5R01CA216265-02
|
$602,394
|
CHRISTENSEN, BROCK
|
DARTMOUTH COLLEGE
|
|
1/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch
|
2U54CA132383-11
|
$1,161,316
|
UNGUEZ, GRACIELA
|
NEW MEXICO STATE UNIVERSITY LAS CRUCES
|
|
1/2 The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities Research
|
3U54CA156734-08S1
|
$64,152
|
COLON-CARMONA, ADAN
|
UNIVERSITY OF MASSACHUSETTS BOSTON
|
|
1/2 TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership
|
1U54CA221705-01A1
|
$1,671,024
|
MA, GRACE
|
TEMPLE UNIV OF THE COMMONWEALTH
|
|
1/2: Partnership to study racial/ethnic differences in GI cancer biology
|
3P20CA192994-04S1
|
$62,420
|
LI, ELLEN
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
1/2: Partnership to study racial/ethnic differences in GI cancer biology
|
3P20CA192994-04S2
|
$48,381
|
LI, ELLEN
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
1/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center
|
1U54CA233396-01
|
$1,008,781
|
REAMS, ROMONIA
|
FLORIDA AGRICULTURAL AND MECHANICAL UNIV
|
|
1/3: The Chicago Collaborative to Promote and Advance Cancer Health Equity
|
5U54CA203000-04
|
$969,219
|
SIMON, MELISSA
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
11th AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved
|
1R13CA236113-01
|
$74,000
|
FOTI, MARGARET
|
AMERICAN ASSOCIATION FOR CANCER RESEARCH
|
|
2/2 Langston University-UNTHSC Partnership for Cancer Research and Education
|
1P20CA233355-01
|
$255,958
|
VISHWANATHA, JAMBOOR
|
UNIVERSITY OF NORTH TEXAS HLTH SCI CTR
|
|
2/2 NCCU-LCCC Partnership in Cancer Research
|
5U54CA156733-09
|
$1,003,901
|
EARP, HENRY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
2/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch
|
2U54CA132381-11
|
$1,439,317
|
SIMON, JULIAN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
2/2 Ponce School of Medicine-Moffitt Cancer Center Partnership
|
5U54CA163068-07
|
$1,751,252
|
MUNOZ-ANTONIA, TERESITA
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
2/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center
|
1U54CA233444-01
|
$1,054,795
|
ODEDINA, FOLAKEMI
|
UNIVERSITY OF FLORIDA
|
|
2/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership
|
5U54CA118623-13
|
$1,101,004
|
TROY, ROBERTA
|
TUSKEGEE UNIVERSITY
|
|
2/3: The Chicago Collaborative to Promote and Advance Cancer Health Equity
|
5U54CA202995-04
|
$789,845
|
CIECIERSKI, CHRISTINA
|
NORTHEASTERN ILLINOIS UNIVERSITY
|
|
2D and 3D Contrast-enhanced Ultrasound Evaluation of HCC Chemoembolization
|
5R01CA194307-03
|
$105,860
|
EISENBREY, JOHN
|
THOMAS JEFFERSON UNIVERSITY
|
|
3/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center
|
1U54CA233465-01
|
$1,141,251
|
CARPTEN, JOHN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
3/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership
|
5U54CA118948-13
|
$1,170,535
|
MANNE, UPENDER
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
3D biomimetic image-based stromal models of pancreatic cancer for drug screening
|
1R21CA224280-01A1
|
$213,829
|
CAMPAGNOLA, PAUL
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
3D Model of Human Ewing Sarcoma
|
3R01CA180279-05S1
|
$221,019
|
MIKOS, ANTONIOS
|
RICE UNIVERSITY
|
|
A biophysical approach to elucidating the molecular mechanisms of mitotic inhibitor targets
|
4K00CA223018-02
|
$80,244
|
MICKOLAJCZYK, KEITH
|
ROCKEFELLER UNIVERSITY
|
|
A cluster randomized trial of a primary palliative care intervention (CONNECT) for patients with advanced cancer
|
5R01CA197103-03
|
$584,861
|
SCHENKER, YAEL
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
A Data Resource for Analyzing Blood and Marrow Transplants
|
3U24CA076518-20S1
|
$1,060,626
|
HOROWITZ, MARY
|
MEDICAL COLLEGE OF WISCONSIN
|
|
A Glycopeptide from Interstitial Cystitis Patients as a Novel Anticancer Lead
|
ZIA BC 011232
|
$314,516
|
Barchi, Joseph
|
CCR (NCI)
|
|
A longitudinal assessment of frailty in young adult survivors of childhood cancer
|
3R01CA174851-05S1
|
$119,204
|
NESS, KIRSTEN
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
A longitudinal assessment of frailty in young adult survivors of childhood cancer
|
5R01CA174851-05
|
$511,226
|
NESS, KIRSTEN
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
A model of smoking relapse: an assessment of stress, discrimination and socioeconomic status
|
3R01CA190329-04S1
|
$115,391
|
WETTER, DAVID
|
UNIVERSITY OF UTAH
|
|
A multi-fluorescent intravital microscopy approach to study osteosarcoma
|
7R21CA208618-02
|
$176,380
|
INTINI, GIUSEPPE
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
A novel diagnostic biomarker for Hepatocellular Carcinoma(HCC)
|
3R44CA165314-04S1
|
$1,400
|
LU, XUANYONG
|
IMCARE BIOTECH
|
|
A pan-cancer role for MutL loss in inducing treatment resistance
|
1K22CA229613-01
|
$147,169
|
HARICHARAN, SVASTI
|
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST
|
|
A Patient-Centered Approach to Integration of Life Expectancy into Treatment Decision Making for Patients with Genitourinary Malignancy
|
1K08CA230155-01
|
$183,258
|
DASKIVICH, TIMOTHY
|
CEDARS-SINAI MEDICAL CENTER
|
|
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
|
4R44CA217591-02
|
$1,125,311
|
KAHN, STUART
|
SYNTRIX BIOSYSTEMS, INC.
|
|
A Phase I Combination Study of Durvalumab and Vicinium in BCG refractory NMIBC
|
ZIA BC 011786
|
$30,836
|
Agarwal, Piyush
|
CCR (NCI)
|
|
A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.
|
3R44CA221513-02S1
|
$4,319
|
DEVENPORT, MARTIN
|
ONCOIMMUNE, INC.
|
|
A Phase III Randomized Trial Targeting Behavioral Symptoms in Younger Breast Cancer Survivors
|
5R01CA200977-03
|
$639,777
|
GANZ, PATRICIA
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
A Prospective Study of the Impact of Breast Cancer on Symptoms and Functioning
|
5R01CA199137-04
|
$55,401
|
AVIS, NANCY
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
|
A Quality Control Program for Quantitative MRI Data Acquisition and Analysis in Multi-site Clinical Trials
|
1R44CA235820-01
|
$224,422
|
KARAULANOV, TODOR
|
QALIBREMD, INC.
|
|
A randomized trial of lifestyle guidelines on breast cancer biomarkers and treatment adherence
|
3R01CA207753-02S2
|
$76,309
|
SANFT, TARA
|
YALE UNIVERSITY
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|